Steve Posnack from ONC declared today IT Bonanza Day. The Interoperability Roadmap, CMS Meaningful Use Final Rules with a Comment Period (Stage 2 and 3) as well as the ONC 2015 Certification Rule were published today.
Here are a few resources to help you navigate these rules
- A press release for today’s announcement
- For more detailed information about today’s announcement
- For more information on the CMS final rule with comment period
- For more information on the ONC final 2015 Edition Certification Rule
- The EHR Incentive Programs final rule itself
- The 2015 Edition Certification final rule itself
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Here’s my first impression:
It remains to be seen how the comment period on the EHR Incentive Programs final rule will be used to align the Meaningful Use program with the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) effort. It would not surprise me that the CMS final rules are not really final.
There will be one Meaningful Use rule that will cover 2016 to 2018 both modifications (to Stage 2) and Stage 3.
The final rules are not substantially different than the proposed rules, but the thresholds have been reduced. Given that existing certified EHRs were created to support the previous Stage 2 thresholds, I’m guessing vendors will have to modify code to support the changes.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
2017 will still be an optional Stage 3 reporting year. 2015 will be a 90 day reporting period for everyone.
Quality measures have not changed, but the industry will have to support other initiatives in merit-based performance that have requirements.
In the upcoming days, I will review the certification criteria in detail. Immature standards such as HPD for provider directory query have been removed. Others such as DS4P for data segmentation are included but are not required.
CMS and ONC have incorporated many of the changes requested by professional organizations and expert commentators, which is a good thing.
I’ll post details and briefs on these rules in the next week.